Pathogenesis of autoimmune myositis: Role of MHC Class 1
Pathogenesis of autoimmune myositis: Role of MHC Class 1
批准号:
7903812
负责人:
KANNEBOYINA NAGARAJU
金额:
$22.43万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-18 至 2011-09-17
关键词:
AddressAutoantibodiesAutoimmune DiseasesAutoimmune ProcessBiochemicalBiochemical PathwayCa(2+)-Transporting ATPaseCalciumCell DeathCell surfaceCellsChildClinicalCollagen ArthritisComplexCytotoxic T-LymphocytesDataDevelopmentDiseaseDistressDistrict of ColumbiaDoxycyclineElectron MicroscopyEmployee StrikesEndoplasmic ReticulumFemaleFiberFigs - dietaryFunctional disorderGRP78 geneGene ExpressionGene Expression ProfilingGene ProteinsGenesGoalsHistocompatibility Antigens Class IHomeostasisHumanImmuneImmune responseInjuryKnockout MiceLymphocyteMajor Histocompatibility ComplexMapsMeasuresMediatingMedical centerModelingModificationMolecularMolecular ProfilingMonitorMotorMotor ActivityMusMuscleMuscle CellsMuscle FibersMuscle functionMyopathyMyositisNF-kappa BNorthern BlottingOnset of illnessPathogenesisPathologyPathway interactionsPatternPhenotypePhysiological ProcessesPlayPolymyositisPost-Translational Protein ProcessingPredispositionProteinsProteomicsPubertyResearch PersonnelReverse Transcriptase Polymerase Chain ReactionRheumatismRoleSarcoplasmic ReticulumSeriesSeveritiesSeverity of illnessSkeletal MuscleStagingTestingThapsigarginTherapeutic InterventionTimeTranscriptional ActivationTransgenesTransgenic MiceWestern Blottingbasebiological adaptation to stresscaspase 12cell injurycell typedefined contributioneffective therapyendoplasmic reticulum stressin vivoinhibitor/antagonistlaser capture microdissectionmacrophagemembermouse modelnovelprogramspromoterprotein expressionreactive oxygen intermediateresearch studyresponseretinal rodssmall moleculetherapeutic targettooltranscription factor CHOPtransgene expression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
Specific therapies are not currently available for systemic autoimmune rheumatic diseases. Development of specific and effective therapies requires the definition of pathways important in the disease pathogcncsis. The MHC class 1 mouse model of myositis is a powerful tool to identify such pathways. The long term goals of this proposal are to define the molecular pathways responsible for the skeletal muscle damage and dysfunction in autoimmune myositis. The MHC class I transgenic mice develop several features of human autoimmune polymyositis including myositis-specific autoantibodies. Preliminary experiments showed that the absence of lymphocytes and macrophages only partially ameliorates muscle fiber damage and dysfunction suggesting that over-expression of MHC class I in myofibers also initiates a specific sequence of ceil autonomous (myofiber) pathways leading to muscle damage. Thus, in this model both immune cells and skeletal muscle cells appear to play a role in the manifestation of full blown autoimmune myositis. Therefore, we propose that skeletal muscle cell damage in MHC class I expressing muscle fibers can partly be induced by cytotoxic T lymphocytes and partly by perturbation of intracellular homeostasis (ER stress response). Our preliminary experiments clearly show that the ER stress response pathway is highly up-regulated in both human myositis and in the mouse model. Defining the contribution of mechanisms of ER stress response and NF-kB pathways in MHC class I-expressing fibers and their role in muscle fiber damage and dysfunction is a major priority of this proposal. This hypothesis is pursued by a) blocking critical members of ER stress response pathway and NF-kB pathways in vivo, and b) identifying novel immune and non-immune pathways mediating muscle fiber damage and dysfunction by gene and protein expression profiling. The proposed aims will not only define predominant mechanisms of muscle fiber damage and dysfunction in vivo in transgenic mice but will also potentially identify new targets for therapeutic intervention in human myositis.
期刊论文(26)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1007/s11926-012-0247-5
发表时间:
2012-06
期刊:
Current rheumatology reports
影响因子:
5
作者:
[Rayavarapu S, Coley W, Nagaraju K]
通讯作者:
Nagaraju K
Elevation of proinflammatory cytokines in patients with Aicardi-Goutieres syndrome.
Aicardi-Goutieres 综合征患者促炎细胞因子升高。
DOI:
10.1212/wnl.0b013e3182872694
发表时间:
2013
期刊:
Neurology
影响因子:
9.9
作者:
[Takanohashi,Asako, Prust,Morgan, Wang,Jichuan, Gordish-Dressman,Heather, Bloom,Miriam, Rice,GillianI, Schmidt,JohannaL, Crow,YanickJ, Lebon,Pierre, Kuijpers,TacoW, Nagaraju,Kanneboyina, Vanderver,Adeline]
通讯作者:
Vanderver,Adeline
The proton pump inhibitor lansoprazole improves the skeletal phenotype in dystrophin deficient mdx mice.
质子泵抑制剂兰索拉唑可改善肌营养不良蛋白缺陷 mdx 小鼠的骨骼表型。
DOI:
10.1371/journal.pone.0066617
发表时间:
2013
期刊:
PloS one
影响因子:
3.7
作者:
[Sali,Arpana, Many,GinaM, Gordish-Dressman,Heather, vanderMeulen,JackH, Phadke,Aditi, Spurney,ChristopherF, Cnaan,Avital, Hoffman,EricP, Nagaraju,Kanneboyina]
通讯作者:
Nagaraju,Kanneboyina
The molecular basis of skeletal muscle weakness in a mouse model of inflammatory myopathy.
炎症性肌病小鼠模型骨骼肌无力的分子基础。
DOI:
10.1002/art.34625
发表时间:
2012-11
期刊:
ARTHRITIS AND RHEUMATISM
影响因子:
--
作者:
[Coley, William, Rayavarapu, Sree, Pandey, Gouri S., Sabina, Richard L., Van der Meulen, Jack H., Ampong, Beryl, Wortmann, Robert L., Rawat, Rashmi, Nagaraju, Kanneboyina]
通讯作者:
Nagaraju, Kanneboyina
DOI:
10.1371/journal.pone.0065468
发表时间:
2013
期刊:
PloS one
影响因子:
3.7
作者:
[Yu Q, Sali A, Van der Meulen J, Creeden BK, Gordish-Dressman H, Rutkowski A, Rayavarapu S, Uaesoontrachoon K, Huynh T, Nagaraju K, Spurney CF]
通讯作者:
Spurney CF
共 17 条
Virus induced genetic changes in the pathogenesis of autoimmune myositis
-
批准号:9226076
-
项目类别:
-
资助金额:$19.97万
-
财政年份:2017
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Dystrophin turnover after exon-skipping
-
批准号:9293874
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2016
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Preclinical drug trial in mouse models of inflammation
-
批准号:8690993
-
项目类别:
-
资助金额:$10.62万
-
财政年份:2011
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Preclinical drug trial in mouse models of inflammation
-
批准号:8242218
-
项目类别:
-
资助金额:$10.62万
-
财政年份:2011
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Preclinical drug trial in mouse models of inflammation
-
批准号:8325061
-
项目类别:
-
资助金额:$10.62万
-
财政年份:2011
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Pathogenesis of autoimmune myositis: Role of MHC Class 1
-
批准号:7197328
-
项目类别:
-
资助金额:$34.63万
-
财政年份:2005
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Pathogenesis of autoimmune myositis: Role of MHC Class 1
-
批准号:7391060
-
项目类别:
-
资助金额:$33.94万
-
财政年份:2005
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Pathogenesis of autoimmune myositis: Role of MHC Class 1
-
批准号:7186420
-
项目类别:
-
资助金额:$21.9万
-
财政年份:2005
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Pathogenesis of autoimmune myositis: Role of MHC Class 1
-
批准号:6926751
-
项目类别:
-
资助金额:$9.98万
-
财政年份:2005
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Pathogenesis of autoimmune myositis: Role of MHC Class 1
-
批准号:7576722
-
项目类别:
-
资助金额:$33.94万
-
财政年份:2005
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Pathogenesis of autoimmune myositis: Role of MHC Class 1
-
批准号:7037612
-
项目类别:
-
资助金额:$35.66万
-
财政年份:2005
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Preclinical dosing optimization: Dosing schedule, tissue
-
批准号:8261239
-
项目类别:
-
资助金额:$17.89万
-
财政年份:--
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Preclinical dosing optimization: Dosing schedule, tissue
-
批准号:8883660
-
项目类别:
-
资助金额:$14.65万
-
财政年份:--
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
In vitro and in vivo functional assays
-
批准号:8102470
-
项目类别:
-
资助金额:$28.49万
-
财政年份:--
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Preclinical dosing optimization: Dosing schedule, tissue
-
批准号:8472516
-
项目类别:
-
资助金额:$13.79万
-
财政年份:--
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Preclinical dosing optimization: Dosing schedule, tissue
-
批准号:8677926
-
项目类别:
-
资助金额:$14.18万
-
财政年份:--
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Preclinical dosing optimization: Dosing schedule, tissue
-
批准号:8380383
-
项目类别:
-
资助金额:$14.47万
-
财政年份:--
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
海外基金